Search Result
Results for "
5-HT1B/1D
" in MedChemExpress (MCE) Product Catalog:
15
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B0229
-
BW-311C90; 311C90
|
5-HT Receptor
Endogenous Metabolite
|
Neurological Disease
|
Zolmitriptan (BW-311C90; 311C90) is a 5-HT1B/1D receptor partial agonist with Kis of 5.01 nM, 0.63 nM, and 63.09 nM for 5-HT1B, 5-HT1D, 5-HT1F receptor, respectively. Zolmitriptan can be used for the research of migraine .
|
-
-
- HY-B0383
-
-
-
- HY-100794
-
|
5-HT Receptor
|
Neurological Disease
|
GR127935 hydrochloride is a potent and orally active 5-HT1D and 5-HT1B receptor antagonist with pKis of 8.5 for both isoforms. GR127935 hydrochloride has 100-fold selectivity for 5-HT1B/1D receptors over 5-HT1A, 5-HT2A, and 5-HT2C receptors. GR127935 hydrochloride can be used in neurological disease research .
|
-
-
- HY-106157
-
-
-
- HY-105082
-
BMS 180048
|
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
|
Avitriptan is a 5-HT1B/1D receptor agonist, with pKis of 7.44 ( 5-HT1B rat), 7.68 ( 5-HT1B human) and 8.36 ( 5-HT1D human). Avitriptan constricts the isolated coronary artery. Avitriptan can be used for migraines .
|
-
-
- HY-107018
-
AR-A 000002
|
5-HT Receptor
|
Neurological Disease
|
AR-A 2 is a selective 5-HT1B receptor antagonist, with high affinity to guinea pig cortex 5HT1B/1D and recombinant guinea pig 5-HT1B receptors (Ki=0.24 and 0.47 nM) and with 10-fold lower affinity to guinea pig 5-HT1D receptor (Ki, 5 nM), and shows an EC50 of 4.5 nM for the guinea pig 5-HT1B receptor; AR-A 2 can be used in the research of depression and anxiety.
|
-
-
- HY-B0229S
-
-
-
- HY-Z4690
-
-
-
- HY-123869
-
|
5-HT Receptor
|
Neurological Disease
|
GR127935 is a potent and orally active 5-HT1D and 5-HT1B receptor antagonist with pKis of 8.5 for both isoforms. GR127935 hydrochloride has 100-fold selectivity for 5-HT1B/1D receptors over 5-HT1A, 5-HT2A, and 5-HT2C receptors. GR127935 can be used in neurological disease research .
|
-
-
- HY-106157A
-
F-11356 mesylate
|
5-HT Receptor
|
Neurological Disease
|
Donitriptan Mesylate is a potent, high efficacy agonist at 5-HT1B/1D receptors with pKis of 9.4 and 9.3, respectively .
|
-
-
- HY-B0383AS
-
-
-
- HY-103091
-
F-11356
|
5-HT Receptor
|
Neurological Disease
|
Donitriptan hydrochloride (F-11356) is a potent, high efficacy agonist at 5-HT1B/1D receptors with pKis of 9.4 and 9.3, respectively .
|
-
-
- HY-W335976
-
|
5-HT Receptor
|
Cancer
|
Almotriptan hydrochloride is a selective agonist of 5-HT 1B/1D Receptor. Almotriptan hydrochloride can used in study of migraine attacks .
|
-
-
- HY-B0383A
-
-
-
- HY-B0197
-
GR-85548A
|
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
Naratriptan is an orally active and selective 5-HT1B/1D receptor agonist. Naratriptan is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC50=0.11 μM for dog basilar artery). Naratriptan also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms .
|
-
-
- HY-132343S
-
|
Isotope-Labeled Compounds
|
Neurological Disease
|
Zolmitriptan N-Oxide-d6 is a deuterium labeled Zolmitriptan N-Oxide. Zolmitriptan N-Oxide is the major metabolite of Zolmitriptan. Zolmitriptan is a 5-HT1B/1D receptor partial agonist .
|
-
-
- HY-B0197A
-
GR-85548A hydrochloride
|
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
Naratriptan (GR-85548A) hydrochloride is a selective 5-HT1B/1D receptor agonist. Naratriptan hydrochloride is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC50=0.11 μM for dog basilar artery). Naratriptan hydrochloride also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan hydrochloride is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms .
|
-
-
- HY-B0197AS
-
GR-85548A d3
|
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
Naratriptan-d3 (GR-85548A-d3) is the deuterium labeled Naratriptan hydrochloride (HY-B0197A). Naratriptan hydrochloride is a selective 5-HT1B/1D receptor agonist. Naratriptan hydrochloride is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC50=0.11 μM for dog basilar artery). Naratriptan hydrochloride also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan hydrochloride is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms .
|
-
-
- HY-B0197S
-
GR-85548A-d3-1
|
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
Naratriptan-d3 (GR-85548A-d3) is the deuterium labeled Naratriptan (HY-B0197). Naratriptan is a selective 5-HT1B/1D receptor agonist. Naratriptan is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC50=0.11 μM for dog basilar artery). Naratriptan also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms .
|
-
-
- HY-B0197AR
-
GR-85548A hydrochloride (Standard)
|
Reference Standards
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
Naratriptan (GR-85548A) hydrochloride (Standard) is the analytical standard of Naratriptan hydrochloride (HY-B0197A). This product is intended for research and analytical applications. Naratriptan is a selective 5-HT1B/1D receptor agonist. Naratriptan is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC50=0.11 μM for dog basilar artery). Naratriptan also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms .
|
-
-
- HY-121392
-
|
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
|
GR 125743 is a selective 5-HT1B/1D receptor antagonist, with pKis of 8.85 and 8.31 for wild-type h5-HT1B and wild-type h5-HT1D, respectively. GR 125743 is used for the research of Parkinson's disease and cardiovascular diseases .
|
-
-
- HY-B0383AS2
-
-
-
- HY-121562
-
|
5-HT Receptor
|
Neurological Disease
|
SB 714786 is a potent and selective 5-hydroxytryptamine 1D (5-HT1D) receptor antagonist. It was developed from the previously reported series of dual 5-HT1 selective 5-hydroxytryptamine reuptake inhibitors (5HT1-SSRIs). SB 714786 is the first reported highly potent and selective 5-HT1D receptor antagonist, providing an extremely useful pharmacological tool for further understanding the role of 5-HT1 receptor subtypes. It has no or very low intrinsic activity against all three receptors. SB 714786 has pKi values of 6.5, 6.7, 9.1 and 6.5 for 5-HT1A, 5-HT1B, 5-HT1D and SerT receptors, respectively, showing high selectivity for 5-HT1D receptors. These properties make SB 714786 a potential tool compound for studying the function of 5-HT1D receptors and the treatment of related diseases.
|
-
-
- HY-W740014
-
183C91; DZT
|
5-HT Receptor
|
Neurological Disease
|
N-Desmethyl Zolmitriptan (183C91; DZT) is the active metabolite of the serotonin (5-HT) receptor subtype 5-HT1B and 5-HT1D agonist Zolmitriptan (HY-B0229). N-Desmethyl Zolmitriptan (183C91; DZT) is an agonist of 5-HT1B receptors and induces constriction in isolated human cerebral arteries (EC50=100 nM).
|
-
-
- HY-116908
-
|
5-HT Receptor
|
Neurological Disease
|
SB-272183 is a selective 5-HT1A, 5-HT1B and 5-HT1D receptor antagonist. In addition, SB-272183 is also a potent and selective ligand for 5-HT1A, 5-HT1B and 5-HT1D receptors in human recombinant and native tissues with pKi values of 8.0, 8.1 and 8.7, respectively. SB-272183 can be used in antidepressant research .
|
-
-
- HY-W700240
-
|
5-HT Receptor
|
Neurological Disease
|
Triazolomethylindole-3-acetic acid is a metabolite of the serotonin (5-HT) receptor subtype 5-HT1B and 5-HT1D agonist Rizatriptan HY-B0206).
|
-
-
- HY-101698B
-
Alnitidan dihydrochloride
|
5-HT Receptor
|
Neurological Disease
Inflammation/Immunology
|
Alniditan (Alnitidan) dihydrochloride is a potent 5-HT1B and 5-HT1D receptors agonist, with IC50s of 1.7 nM and 1.3 nM for h5-HT1B and h5-HT1D receptors in HEK293 cells, respectively. Alniditan dihydrochloride has migraine-preventive effects .
|
-
-
- HY-101698
-
Alnitidan
|
5-HT Receptor
|
Neurological Disease
Inflammation/Immunology
|
Alniditan (Alnitidan) is a potent 5-HT1B and 5-HT1D receptors agonist, with IC50s of 1.7 nM and 1.3 nM for h5-HT1B and h5-HT1D receptors in HEK293 cells, respectively. Alniditan has migraine-preventive effects .
|
-
-
- HY-A0010
-
Eletriptan HBr; UK-116044 hydrobromide
|
5-HT Receptor
|
Neurological Disease
|
Eletriptan hydrobromide (Eletriptan HBr) is a 5-HT1B and 5-HT1D receptor agonist with antimigraine activity, with Ki of 0.92 nM and 3.14 nM, respectively .
|
-
-
- HY-A0039S
-
-
-
- HY-B0206
-
MK 462
|
5-HT Receptor
|
Neurological Disease
|
Rizatriptan benzoate is the agonist for 5-HT1B and 5-HT1D. Rizatriptan benzoate has a peripheral vasoconstrictive effect, penetrates the intact blood-brain barrier, and inhibits pain neurotransmission in the central nervous system .
|
-
-
- HY-103199
-
SDZ21009
|
5-HT Receptor
|
Neurological Disease
|
Carpindolol (SDZ21009) is a 5-HT1B receptor antagonist (pKd of 8.53 and pKB of 8.0) and a 5-HT1D receptor agonist (pEC50 of 5.91 and pKd of 6.37) .
|
-
-
- HY-W018475B
-
MK 462 hemisulfate hemihydrate
|
5-HT Receptor
|
Neurological Disease
|
Rizatriptan (MK 462) hemisulfate hemihydrate is the agonist for 5-HT1B and 5-HT1D. Rizatriptan hemisulfate hemihydrate has a peripheral vasoconstrictive effect, penetrates the intact blood-brain barrier, and inhibits pain neurotransmission in the central nervous system .
|
-
-
- HY-103151A
-
|
5-HT Receptor
|
Others
|
CP94253 is a selective, orally active agonist for serotonin receptor 1B (5-HT1B), through competitive binding with iodocyanopindolol (ICP) to the 5-HT1 receptor. CP94253 binds to the 5-HT1B, 5-HT1A, 5-HT1D, 5-HT1C and 5-HT2 receptors, with Kis of 2, 89, 49, 860 and 1600 nM. CP94253 causes satiety, anorexia, weight loss and hyperlocomotion in rats model .
|
-
-
- HY-10847
-
SB-277011A
|
Dopamine Receptor
|
Neurological Disease
|
SB-277011 is a potent and delective dopamine D3 receptor antagonist (pKi values are 8.0, 6.0, 5.0 and <5.2 for D3, D2, 5-HT1D and 5-HT1B respectively); brain penetrant.
|
-
-
- HY-B1658B
-
(R)-Frovatriptan succinate; SB 209509 succinate; VML 251 succinate
|
5-HT Receptor
|
Neurological Disease
|
Frovatriptan succinate ((R)-Frovatriptan succinate) is a potent, high affinity, selective and orally active 5-HT1B (pK50 of 8.2) and 5-HT1D receptor agonist. Frovatriptan succinate exhibits >10-fold selectivity for 5-HT1B and 5-HT1D over 5-HT1A, 5-HT1F, and 5-HT7 and >1000-fold selectivity over other 5-HT, dopamine, histamine H1, and α1-adrenoceptor. Frovatriptan succinate has the potential for migraine research .
|
-
-
- HY-B1658A
-
(R)-Frovatriptan succinate hydrate; SB 209509 succinate hydrate; VML 251 succinate hydrate
|
5-HT Receptor
|
Neurological Disease
|
Frovatriptan succinate hydrate ((R)-Frovatriptan succinate hydrate) is a potent, high affinity, selective and orally active 5-HT1B (pK50 of 8.2) and 5-HT1D receptor agonist. Frovatriptan succinate hydrate exhibits >10-fold selectivity for 5-HT1B and 5-HT1D over 5-HT1A, 5-HT1F, and 5-HT7 and >1000-fold selectivity over other 5-HT, dopamine, histamine H1, and α1-adrenoceptor. Frovatriptan succinate hydrate has the potential for migraine research .
|
-
-
- HY-100942
-
5-CT maleate
|
5-HT Receptor
|
Neurological Disease
|
5-Carboxamidotryptamine maleate (5-CT maleate) is a potent 5-HT1A, 5-HT1B, 5-HT1D, 5-HT5 and 5-HT7 receptors agonist .
|
-
-
- HY-117575
-
|
5-HT Receptor
|
Neurological Disease
|
WAY-100135 is a serotonergic compound belonging to the phenylpiperazine family, utilized in scientific research for its role as a strong antagonist of the 5-HT1A receptor and a partial agonist of the 5-HT1D receptor, with minimal activity at the 5-HT1B receptor.
|
-
-
- HY-103131
-
|
5-HT Receptor
|
Neurological Disease
|
PNU-142633 is a high affinity, selective and orally active 5-HT1D receptor agonist with Kis of 6 nM and > 18 000 nM for human 5-HT1D receptor and human 5-HT1B receptor, respectively. PNU-142633 has anti-migraine efficacy .
|
-
-
- HY-A0039
-
UK-116044
|
5-HT Receptor
|
Neurological Disease
Inflammation/Immunology
|
Eletriptan (UK-116044) is a highly selective and orally active serotonin 5-HT1B and 5-HT1D receptor agonist, with pKi values of 8.0 and 8.9, respectively. Eletriptan has inhibitory effects on markers of neurogenic inflammation in rats. Eletriptan can be used for researching migraine .
|
-
-
- HY-A0010R
-
Eletriptan HBr (Standard); UK-116044 hydrobromide (Standard)
|
Reference Standards
5-HT Receptor
|
Neurological Disease
|
Eletriptan hydrobromide (Standard) is an analytical standard for Eletriptan hydrobromide. This product is intended for research and analytical applications. Eletriptan hydrobromide (Eletriptan HBr) is a 5-HT1B and 5-HT1D receptor agonist with antimigraine activity, with Ki of 0.92 nM and 3.14 nM, respectively .
|
-
-
- HY-B0206S
-
|
Isotope-Labeled Compounds
5-HT Receptor
|
Neurological Disease
|
Rizatriptan-d6 (benzoate) is the deuterium labeled Rizatriptan benzoate. Rizatriptan benzoate is the agonist for 5-HT1B and 5-HT1D. Rizatriptan benzoate has a peripheral vasoconstrictive effect, penetrates the intact blood-brain barrier, and inhibits pain neurotransmission in the central nervous system .
|
-
-
- HY-103089
-
|
5-HT Receptor
|
Neurological Disease
|
LY393558 is a potent and orally active inhibitor of the 5-HT transporter and an antagonist of 5-HT1B and 5-HT1D receptors. LY393558 increase the extracellular levels of 5-HT in mice model frontal cortex. LY393558 can be used for researching depression .
|
-
-
- HY-B1658BS
-
(R)-Frovatriptan-d3 succinate; SB 209509-d3 succinate; VML 251-d3 succinate
|
Isotope-Labeled Compounds
5-HT Receptor
|
Neurological Disease
|
Frovatriptan-d3 (succinate) is deuterium labeled Frovatriptan (succinate). Frovatriptan succinate ((R)-Frovatriptan succinate) is a potent, high affinity, selective and orally active 5-HT1B (pK50 of 8.2) and 5-HT1D receptor agonist. Frovatriptan succinate exhibits >10-fold selectivity for 5-HT1B and 5-HT1D over 5-HT1A, 5-HT1F, and 5-HT7 and >1000-fold selectivity over other 5-HT, dopamine, histamine H1, and α1-adrenoceptor. Frovatriptan succinate has the potential for migraine research .
|
-
-
- HY-B1658AR
-
(R)-Frovatriptan succinate hydrate (Standard); SB 209509 succinate hydrate (Standard); VML 251 succinate hydrate (Standard)
|
Reference Standards
5-HT Receptor
|
Neurological Disease
|
Frovatriptan (succinate hydrate) (Standard) is the analytical standard of Frovatriptan (succinate hydrate). This product is intended for research and analytical applications. Frovatriptan succinate hydrate ((R)-Frovatriptan succinate hydrate) is a potent, high affinity, selective and orally active 5-HT1B (pK50 of 8.2) and 5-HT1D receptor agonist. Frovatriptan succinate hydrate exhibits >10-fold selectivity for 5-HT1B and 5-HT1D over 5-HT1A, 5-HT1F, and 5-HT7 and >1000-fold selectivity over other 5-HT, dopamine, histamine H1, and α1-adrenoceptor. Frovatriptan succinate hydrate has the potential for migraine research .
|
-
-
- HY-B0206R
-
MK 462 (Standard)
|
Reference Standards
5-HT Receptor
|
Neurological Disease
|
Rizatriptan (benzoate) (Standard) is the analytical standard of Rizatriptan (benzoate). This product is intended for research and analytical applications. Rizatriptan benzoate is the agonist for 5-HT1B and 5-HT1D. Rizatriptan benzoate has a peripheral vasoconstrictive effect, penetrates the intact blood-brain barrier, and inhibits pain neurotransmission in the central nervous system .
|
-
-
- HY-10847A
-
SB-277011A dihydrochloride
|
Dopamine Receptor
|
Neurological Disease
|
SB-277011 dihydrochloride (SB-277011A dihydrochloride) is a potent, selective, orally bioavailable and brain penetrate dopamine D3 receptor antagonist, with pKis of 8.0, 6.0, <5.2 and 5.9 for D3, D2, 5-HT1B, and 5-HT1D receptors, respectively.
|
-
-
- HY-W022362
-
|
Serotonin Transporter
|
Neurological Disease
|
2-Aminotetralin is a potent and selective serotonin 5-HT1 agonist. 2-Aminotetralin exhibits high affinity (Ki≤25 nM) and at least 50-fold stereoselective preference at 5-HT1A, 5-HT1B, and 5-HT1D receptors .
|
-
-
- HY-120688
-
|
5-HT Receptor
|
Neurological Disease
|
L-772405 is a selective 5-HT1D receptor agonist with the Ki values of 318, 29 and > 1000 nM aganist guinea pig 5-HT1B receptor, guinea pig 5-HT1D receptor and rat 5-HT rransporter, respectively. L-772405 decreases the potassium-induced outflow of 5-HT with an IC50 value of 240 nM .
|
-
- HY-A0039S1
-
|
5-HT Receptor
|
Inflammation/Immunology
|
Eletriptan-d5 is the deuterium labeled Eletriptan . Eletriptan (UK-116044) is a highly selective and orally active serotonin 5-HT1B and 5-HT1D receptor agonist, with pKi values of 8.0 and 8.9, respectively. Eletriptan has inhibitory effects on markers of neurogenic inflammation in rats. Eletriptan can be used for researching migraine .
|
-
- HY-124117
-
|
5-HT Receptor
|
Neurological Disease
|
LY 278584 is a potent, highly selective 5-HT3 receptor antagonist with a Ki of 1.62 nM. LY 278584 has no activity on 5-HT1A, 5-HT1B, 5-HT1C, 5-HT1D, or 5-HT2 receptors .
|
-
- HY-A0039S2
-
|
5-HT Receptor
|
Inflammation/Immunology
|
Eletriptan-d5 (hydrochloride) is the deuterium labeled Eletriptan hydrochloride . Eletriptan (UK-116044) hydrochloride is a highly selective and orally active serotonin 5-HT1B and 5-HT1D receptor agonist, with pKi values of 8.0 and 8.9, respectively. Eletriptan hydrochloride has inhibitory effects on markers of neurogenic inflammation in rats. Eletriptan hydrochloride can be used for researching migraine .
|
-
- HY-B0121BS1
-
GR 43175 free base-d6
|
Isotope-Labeled Compounds
5-HT Receptor
|
Neurological Disease
|
Sumatriptan-d6 is the deuterium labeled Sumatriptan. Sumatriptan is an orally active 5-HT1 receptor agonist with Kis of 17 nM, 27 nM and 100 nM for 5-HT1D, 5-HT1B and 5-HT1A receptors, respectively. Sumatriptan can be used for migraine headache research .
|
-
- HY-B0121B
-
GR 43175 free base
|
5-HT Receptor
|
Neurological Disease
|
Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan can be used for migraine headache research .
|
-
- HY-B0121A
-
GR 43175 hydrochloride
|
5-HT Receptor
|
Neurological Disease
|
Sumatriptan hydrochloride (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan hydrochloride can be used for migraine headache research .
|
-
- HY-B0121BS
-
GR 43175C-d6
|
5-HT Receptor
Isotope-Labeled Compounds
|
Neurological Disease
|
Sumatriptan-d6 succinate is the deuterium labeled Sumatriptan succinate. Sumatriptan succinate is an orally active 5-HT1 receptor agonist with Kis of 17 nM, 27 nM and 100 nM for 5-HT1D, 5-HT1B and 5-HT1A receptors, respectively. Sumatriptan succinate can be used for migraine headache research .
|
-
- HY-103151
-
|
5-HT Receptor
|
Neurological Disease
|
CP94253 hydrochloride is a potent and selective agonist of 5-HT1B receptor (Ki= 2 nM in a radioligand binding assay).Ki values for 5-HT1A, 5-HT1D, 5-HT1C and 5-HT2 receptors are 89, 49, 860, and 1600 nM respectively . CP94253 hydrochloride is centrally active upon systemic administration in vivo .
|
-
- HY-13527
-
|
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
|
LY310762 is a selective 5-HT1D receptor antagonist (Ki=249 nM) with a weak affinity for 5-HT1B receptor. LY310762 effectively abolishes the renal vasodilatory effects of 5-HTSumatriptan (HY-B0121B)-induced decrease in excitatory postsynaptic potential (EPSC) amplitude .
|
-
- HY-B0121
-
GR 43175 succinate
|
5-HT Receptor
|
Neurological Disease
|
Sumatriptan succinate (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan succinate can be used for migraine headache research .
|
-
- HY-123704
-
|
5-HT Receptor
|
Neurological Disease
|
CGS-12066 (maleate) is a 5-HT receptor agonist. CGS-12066 has agonist effect for 5-HT1A , 5-HT1B ,5-HT1C and 5-HT1D with pEC50 values of 6.41, 7.56, 4.05 and 7.11, respectively. CGS-12066 can be used for the research of neurological disease .
|
-
- HY-B0121R
-
GR 43175 succinate (Standard)
|
5-HT Receptor
Reference Standards
|
Neurological Disease
|
Sumatriptan (succinate) (Standard) is the analytical standard of Sumatriptan (succinate). This product is intended for research and analytical applications. Sumatriptan succinate (GR 43175) is an orally active 5-HT1 receptor agonist with Kis of 17 nM, 27 nM and 100 nM for 5-HT1D, 5-HT1B and 5-HT1A receptors, respectively. Sumatriptan succinate can be used for migraine headache research .
|
-
- HY-B0121BR
-
|
5-HT Receptor
|
Neurological Disease
|
Sumatriptan (Standard) is the analytical standard of Sumatriptan. This product is intended for research and analytical applications. Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan can be used for migraine headache research .
|
-
- HY-19283
-
|
5-HT Receptor
|
Neurological Disease
|
DU125530 is a potent and selective5-HT1A receptor antagonist with Ki values of 0.7, 890, 1200, 240, 750, 1100 nM for 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2C, 5-HT3, respectively. DU125530 shows antidepressant effects .
|
-
- HY-135555
-
5-CT
|
5-HT Receptor
|
Neurological Disease
|
5-Carboxamidotryptamine (5-CT) is a 5-HT1A, 5-HT1B, 5-HT1D, 5-HT5A, 5-HT7 receptor agonist . 5-Carboxamidotryptamine has a Ki value of 4.6 nM for cloned human 5-HT5A receptor. 5-Carboxamidotryptamine causes a dose-dependent reduction in rectal temperature of mice .
|
-
- HY-B0121BS2
-
GR 43175 free base-d5
|
5-HT Receptor
Isotope-Labeled Compounds
|
Neurological Disease
|
Sumatriptan-d5 is deuterated labeled Sumatriptan (HY-B0121B). Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan can be used for migraine headache research .
|
-
- HY-103142
-
|
5-HT Receptor
|
Neurological Disease
|
AS19 is a potent, selective 5-HT7 receptor agonist with an IC50 value of 0.83 nM and a Ki of 0.6 nM. AS19 is selective for 5-HT7 over 5-HT1A, 5-HT1B, 5-HT1D, and 5-HT5A receptors (Kis = 89.7 nM, 490 nM, 6.6 nM and 98.5 nM, respectively). AS19 enhances memory consolidation and reverses Scopolamine- or Dizocilpine-induced amnesia .
|
-
- HY-B0121BS3
-
GR 43175 free base-d6 formate
|
Isotope-Labeled Compounds
5-HT Receptor
|
Neurological Disease
|
Sumatriptan-d6 (formate) (GR 43175 free base-d6 (formate)) is deuterium labeled Sumatriptan. Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan can be used for migraine headache research .
|
-
- HY-10847B
-
SB-277011A hydrochloride
|
Dopamine Receptor
5-HT Receptor
|
Neurological Disease
|
SB-277011 hydrochloride (SB-277011A hydrochloride) is a potent, selective, orally bioavailable and brain penetrate dopamine D3 receptor (D3R) antagonist with Ki values of 10.7 nM and 11.2 nM at rodent and human D3R, respectively. SB-277011 hydrochloride displays 80- to 100-fold selectivity over other dopamine receptors with pKis of 8.0, 6.0, <5.2, and 5.9 for D3, D2, 5-HT1B, and 5-HT1D receptors, respectively .
|
-
- HY-103149
-
SB-216641 hydrochloride
|
5-HT Receptor
|
Neurological Disease
|
SB-216641A (SB-216641 hydrochloride) is a selective antagonist of 5-HT1B/D receptor. SB-216641A shows high affinity and selectivity for h5-HT1B receptors over h5-HT1D receptors. SB-216641A inhibits the function of SKF-99101H .
|
-
- HY-101009
-
Metitepine maleate; Ro-8-6837 maleate
|
5-HT Receptor
|
Neurological Disease
|
Methiothepin maleate is a potent and non-selective 5-HT2 receptor antagonist, with pKds of 7.10 (5-HT1A), 7.28 (5HT1B), 7.56 (5HT1C), 6.99 (5HT1D), 7.0 (5-HT5A), 7.8 (5-HT5B), 8.74 (5-HT6), and 8.99 (5-HT7), and pKis of 8.50 (5HT2A), 8.68 (5HT2B), and 8.35 (5HT2C).
|
-
- HY-107836
-
Metitepine mesylate; Ro 8-6837 mesylate
|
5-HT Receptor
|
Neurological Disease
|
Methiothepin (Metitepine) mesylate is a potent and non-selective 5-HT2 receptor antagonist, with pKds of 7.10 (5-HT1A), 7.28 (5HT1B), 7.56 (5HT1C), 6.99 (5HT1D), 7.0 (5-HT5A), 7.8 (5-HT5B), 8.74 (5-HT6), and 8.99 (5-HT7), and pKis of 8.50 (5HT2A), 8.68 (5HT2B), and 8.35 (5HT2C).
|
-
- HY-111491
-
Metitepine; Ro 8-6837
|
5-HT Receptor
|
Neurological Disease
|
Methiothepin (Metitepine; Ro 8-6837) is a potent and non-selective 5-HT2 receptor antagonist, with pKds of 7.10 (5-HT1A), 7.28 (5HT1B), 7.56 (5HT1C), 6.99 (5HT1D), 7.0 (5-HT5A), 7.8 (5-HT5B), 8.74 (5-HT6), and 8.99 (5-HT7), and pKis of 8.50 (5HT2A), 8.68 (5HT2B), and 8.35 (5HT2C).
|
-
- HY-107836R
-
|
5-HT Receptor
|
Neurological Disease
|
Methiothepin (mesylate) (Standard) is the analytical standard of Methiothepin (mesylate). This product is intended for research and analytical applications. Methiothepin (Metitepine) mesylate is a potent and non-selective 5-HT2 receptor antagonist, with pKds of 7.10 (5-HT1A), 7.28 (5HT1B), 7.56 (5HT1C), 6.99 (5HT1D), 7.0 (5-HT5A), 7.8 (5-HT5B), 8.74 (5-HT6), and 8.99 (5-HT7), and pKis of 8.50 (5HT2A), 8.68 (5HT2B), and 8.35 (5HT2C).
|
-
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0229S
-
|
Zolmitriptan-d6 is deuterium labeled Zolmitriptan. Zolmitriptan (BW-311C90; 311C90) is a 5-HT1B/1D receptor partial agonist with Kis of 5.01 nM, 0.63 nM, and 63.09 nM for 5-HT1B, 5-HT1D, 5-HT1F receptor, respectively. Zolmitriptan can be used for the research of migraine .
|
-
-
- HY-B0383AS
-
|
Almotriptan-d6 hydrochloride is the deuterium labeled Almotriptan. Almotriptan is a 5-HT1B/1D-receptor agonist used to treat migraine.
|
-
-
- HY-132343S
-
|
Zolmitriptan N-Oxide-d6 is a deuterium labeled Zolmitriptan N-Oxide. Zolmitriptan N-Oxide is the major metabolite of Zolmitriptan. Zolmitriptan is a 5-HT1B/1D receptor partial agonist .
|
-
-
- HY-B0197AS
-
|
Naratriptan-d3 (GR-85548A-d3) is the deuterium labeled Naratriptan hydrochloride (HY-B0197A). Naratriptan hydrochloride is a selective 5-HT1B/1D receptor agonist. Naratriptan hydrochloride is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC50=0.11 μM for dog basilar artery). Naratriptan hydrochloride also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan hydrochloride is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms .
|
-
-
- HY-B0197S
-
|
Naratriptan-d3 (GR-85548A-d3) is the deuterium labeled Naratriptan (HY-B0197). Naratriptan is a selective 5-HT1B/1D receptor agonist. Naratriptan is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC50=0.11 μM for dog basilar artery). Naratriptan also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms .
|
-
-
- HY-B0383AS2
-
|
Almotriptan-d3 benzoate is deuterated labeled Almotriptan (HY-B0383A). Almotriptan is a selective agonist of 5-HT 1B/1D Receptor. Almotriptan can used in study of migraine attacks .
|
-
-
- HY-A0039S
-
|
Eletriptan-d3 is the deuterium labeled Eletriptan hydrobromide. Eletriptan hydrobromide is a selective 5-HT1B and 5-HT1D receptor agonist with Ki of 0.92 nM and 3.14 nM, respectively .
|
-
-
- HY-B0206S
-
|
Rizatriptan-d6 (benzoate) is the deuterium labeled Rizatriptan benzoate. Rizatriptan benzoate is the agonist for 5-HT1B and 5-HT1D. Rizatriptan benzoate has a peripheral vasoconstrictive effect, penetrates the intact blood-brain barrier, and inhibits pain neurotransmission in the central nervous system .
|
-
-
- HY-B1658BS
-
|
Frovatriptan-d3 (succinate) is deuterium labeled Frovatriptan (succinate). Frovatriptan succinate ((R)-Frovatriptan succinate) is a potent, high affinity, selective and orally active 5-HT1B (pK50 of 8.2) and 5-HT1D receptor agonist. Frovatriptan succinate exhibits >10-fold selectivity for 5-HT1B and 5-HT1D over 5-HT1A, 5-HT1F, and 5-HT7 and >1000-fold selectivity over other 5-HT, dopamine, histamine H1, and α1-adrenoceptor. Frovatriptan succinate has the potential for migraine research .
|
-
-
- HY-A0039S1
-
|
Eletriptan-d5 is the deuterium labeled Eletriptan . Eletriptan (UK-116044) is a highly selective and orally active serotonin 5-HT1B and 5-HT1D receptor agonist, with pKi values of 8.0 and 8.9, respectively. Eletriptan has inhibitory effects on markers of neurogenic inflammation in rats. Eletriptan can be used for researching migraine .
|
-
-
- HY-A0039S2
-
|
Eletriptan-d5 (hydrochloride) is the deuterium labeled Eletriptan hydrochloride . Eletriptan (UK-116044) hydrochloride is a highly selective and orally active serotonin 5-HT1B and 5-HT1D receptor agonist, with pKi values of 8.0 and 8.9, respectively. Eletriptan hydrochloride has inhibitory effects on markers of neurogenic inflammation in rats. Eletriptan hydrochloride can be used for researching migraine .
|
-
-
- HY-B0121BS1
-
|
Sumatriptan-d6 is the deuterium labeled Sumatriptan. Sumatriptan is an orally active 5-HT1 receptor agonist with Kis of 17 nM, 27 nM and 100 nM for 5-HT1D, 5-HT1B and 5-HT1A receptors, respectively. Sumatriptan can be used for migraine headache research .
|
-
-
- HY-B0121BS
-
1 Publications Verification
|
Sumatriptan-d6 succinate is the deuterium labeled Sumatriptan succinate. Sumatriptan succinate is an orally active 5-HT1 receptor agonist with Kis of 17 nM, 27 nM and 100 nM for 5-HT1D, 5-HT1B and 5-HT1A receptors, respectively. Sumatriptan succinate can be used for migraine headache research .
|
-
-
- HY-B0121BS2
-
|
Sumatriptan-d5 is deuterated labeled Sumatriptan (HY-B0121B). Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan can be used for migraine headache research .
|
-
-
- HY-B0121BS3
-
|
Sumatriptan-d6 (formate) (GR 43175 free base-d6 (formate)) is deuterium labeled Sumatriptan. Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan can be used for migraine headache research .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: